Deeter Investments’s Roivant Sciences ROIV Stock Holding History

Deeter Investments’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,485	Closed	-$1.56M	–	137
2026 Q1	$1.56M	Hold	56,485	–	–	0.18%	76
2025 Q4	$1.23M	Buy	+56,485	New	+$1.11M	0.26%	54

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Deeter Investments's ROIV Position: Q2 2026 in Review

Deeter Investments sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 56,485 shares — an estimated $1.56M sold.

Deeter Investments first reported a position in ROIV in Q4 2025 and held it in 2 quarters. The position peaked at $1.56M in Q1 2026. 501 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Deeter Investments reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Deeter Investments sold 56,485 Roivant Sciences shares in Q2 2026, an estimated $1.56M.
Deeter Investments first reported a position in Roivant Sciences in Q4 2025 and held it in 2 quarters.
Deeter Investments's Roivant Sciences position peaked at $1.56M in Q1 2026.
501 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.